Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16931587 | 1.00 | TSHR (0.40) | TSHRCYP19A1ALDH1A1MAPTKDM4E | |
| SCHEMBL15721091 | 1.00 | TSHR (0.40) | TSHRCYP19A1ALDH1A1MAPTKDM4E | |
| SCHEMBL16106194 | 1.00 | TSHR (0.40) | TSHRCYP19A1ALDH1A1MAPTKDM4E | |
| SCHEMBL15517115 | 1.00 | TSHR (0.40) | TSHRCYP19A1ALDH1A1MAPTKDM4E | |
| SCHEMBL19224011 | 0.94 | ALDH1A1 (0.44) | TSHRCYP19A1ALDH1A1MAPTRECQL | |
| SCHEMBL15071344 | 0.91 | KDM4E (0.41) | TSHRALDH1A1MAPTKDM4ERECQL | |
| SCHEMBL12299798 | 0.91 | ALDH1A1 (0.48) | TSHRALDH1A1MAPTKDM4ERECQL | |
| SCHEMBL15720868 | 0.86 | APP (0.50) | TSHRCYP19A1ALDH1A1MAPTHRH3 | |
| SCHEMBL4168797 | 0.84 | ALDH1A1 (0.55) | TSHRALDH1A1KDM4ERECQLCYP3A4 | |
| SCHEMBL10757339 | 0.84 | ALDH1A1 (0.55) | TSHRALDH1A1MAPTKDM4ERECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2981535-B1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | TOPIVERT PHARMA LTD (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-10435361-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-10-08 | — | — | US | disclosed |
| US-20180044288-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-02-15 | — | — | US | disclosed |
| US-9890185-B2 | Urea derivatives useful as kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-02-13 | — | — | US | disclosed |
| US-9796742-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-10-24 | — | — | US | disclosed |
| US-9790209-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-9790174-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-9783556-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-10-10 | — | — | US | disclosed |
| US-9771353-B2 | Kinase inhibitors based upon N-alkyl pyrazoles | TOPIVERT PHARMA LIMITED (GB) | 2017-09-26 | — | — | US | disclosed |
| US-9732063-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| WO-2015092423-A1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
| US-20150166483-A1 | KINASE INHIBITORS | RESPIVERT LTD (GB) | 2015-06-18 | — | — | US | disclosed |
| WO-2014162126-A1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014162121-A1 | KINASE INHIBITORS BASED UPON N-ALKYL PYRAZOLES | TOPIVERT PHARMA LIMITED (GB) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014162126-A1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-10-09 | — | — | WO | disclosed |
| US-20140296208-A1 | KINASE INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| WO-2014076484-A1 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014033446-A1 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014033449-A1 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014033447-A2 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044288-A1 | KINASE INHIBITORS | SYK, LYN, BTK | TSHR 1512/4885CYP19A1 2615/4885ALDH1A1 4408/4885 |
| US-20150166483-A1 | KINASE INHIBITORS | LCK, SYK, FYN | TSHR 3858/4885CYP19A1 3656/4885ALDH1A1 4277/4885 |
| US-10435361-B2 | Kinase inhibitors | SYK, LYN, BTK | TSHR 1512/4885CYP19A1 2615/4885ALDH1A1 4408/4885 |
| US-20140296208-A1 | KINASE INHIBITORS | SYK, LYN, BTK | TSHR 1512/4885CYP19A1 2615/4885ALDH1A1 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.